Clinical Trials
36 trialsCombination of Toripalimab and JS004 Therapy for ccRCC
Fudan University
MRI
University of Chicago
Sorafenib in Treating Patients With Metastatic or Unresectable Kidney Cancer
University of Nebraska
Evaluate the Efficacy of Sorafenib in Renal Cell Carcinoma Patients After a Radical Resection of the Metastases
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Exploratory Study of Radium-223 and VEGF-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Mets
Dana-Farber Cancer Institute
Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery
Alliance for Clinical Trials in Oncology
Sorafenib in Treating Patients With Locally Advanced or Metastatic Kidney Cancer
Northwestern University
BERAT
Central European Society for Anticancer Drug Research
Sorafenib Combined With Chemotherapy for Renal Collecting Duct Carcinoma
Peking University Cancer Hospital & Institute
Personalized Targeted Inhibitors Treatment in Renal Cell Cancer
The University of Texas Health Science Center, Houston
TOKIO
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
SOAP
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Evaluate Safety and Tolerability in Dose Escalation of Sorafenib in Advanced Renal Cell Cancer
University of Kansas Medical Center
Efficacy and Safety of Bevacizumab Plus Sorafenib for the Third-line Treatment in Metastatic Renal Cancer Patients
Peking University Cancer Hospital & Institute
NRR
UNC Lineberger Comprehensive Cancer Center
Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)
M.D. Anderson Cancer Center
Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer
The Methodist Hospital Research Institute
Phase I/II Trial of RAD001 Plus Nexavar in Patients With Kidney Cancer
The Methodist Hospital Research Institute
Pre-operative Administration of Sorafenib in Patients With Metastatic Renal Cell Carcinoma Undergoing Kidney Removal
University Health Network, Toronto
SERCC
Centro di Riferimento Oncologico - Aviano
Velcade and Sorafenib in Unresected or Metastatic Renal Cell Carcinoma
New Mexico Cancer Research Alliance
Study of Sorafenib and Palliative Radiotherapy in Kidney Cancer That Spreads to the Bone
University Health Network, Toronto
Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer
Stanford University
PEG-Interferon Alfa-2b and Sorafenib in Treating Patients With Unresectable or Metastatic Kidney Cancer
Ohio State University Comprehensive Cancer Center
Profile of Soluble and Cellular Biomarkers and of Functional Imaging During Antiangiogenic Therapies in Cancer Patients
Medical University Innsbruck
Sorafenib and RAD001 Renal Cell Carcinoma
University of California, San Francisco
Sorafenib in Treating Patients With Metastatic Kidney Cancer That Has Not Responded to Sunitinib or Bevacizumab
Case Comprehensive Cancer Center
Sequential Study to Treat Renal Cell Carcinoma
Sponsor GmbH
Effect of Sorafenib on ccRCC Uptake of Radiolabeled Bevacizumab or cG250
Radboud University Medical Center
Randomized Study of Sorafenib Dose Escalation in Patients With Previously Untreated Metastatic Renal Cell Carcinoma
Accelerated Community Oncology Research Network
Phase I Study of Vorinostat and Sorafenib in Advanced Cancer
University of Colorado, Denver
Everolimus/Sorafenib or Sunitinib in Patients With Metastatic Renal Cell Carcinoma (RCC)
University of California, San Francisco
Efficacy and Safety of Sorafenib in Advanced Renal Cell Carcinoma (RCC)
Mahidol University
MERITS
Egyptian Foundation For Cancer Research
ROSORC
Italian Trial in Medical Oncology
SOGUG-02-06
Spanish Oncology Genito-Urinary Group